MEDICAL BIOLOGICAL DEFENSE (BASIC RESEARCH)

Abstract

This project (TB1) funds basic research of vaccines, diagnostic tools, and therapeutic drugs to provide effective medical defense against validated biological threat agents including bacteria, toxins, and viruses. Advance innovative biotechnology approaches with the potential to rapidly identify, diagnose, prevent, and treat disease due to exposure to biological threat agents. Project categories include core science efforts and technology programs areas in biological defense capability areas, such as Pretreatments, Diagnostics, and Therapeutics. Starting in FY10, all efforts will be combined into a single capability area called Biological Based Basic Research. This project also includes efforts such as the Transformational Medical Technologies Initiative (TMTI). The TMTI was launched to respond to the threat of emerging or intentionally bioengineered biological threats. TMTI's mission is to protect the Warfighter from genetically engineered biological threats by providing a rapid response capability from identification of pathogens to the delivery of medical countermeasures. This mission is accomplished through two main efforts: 1) developing broad spectrum (multi-agent) therapeutics against biological warfare (BW) agents (e.g, one drug that treats multiple agents); and 2) developing platform technologies to assist in the rapid development of medical countermeasures (MCMs) in response to BW agents (e.g, developing new and innovative ways to mass produce drugs in the event of a biological incident).

Document Details

• Document Type: Project
• Publication Date: Oct 01, 2011
• Source ID: TB1_0601384BP_1_0400_PB_2011

Tags

Fields of Study

• Biology

Readers

• Critical Infrastructure Protection in CBRN and WMD Threats.

Technology Areas

• Biotechnology